+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Risk factors associated with a new pregnancy loss and perinatal outcomes in cases of recurrent miscarriage treated with lymphocyte immunotherapy



Risk factors associated with a new pregnancy loss and perinatal outcomes in cases of recurrent miscarriage treated with lymphocyte immunotherapy



Journal of Maternal-Fetal and Neonatal Medicine 28(9): 1082-1086



To assess the perinatal outcomes and risk factors for further pregnancy loss in patients with recurrent miscarriage treated with lymphocyte immunotherapy (LIT). We performed a retrospective observational study of women with a history of two or more consecutive miscarriages who underwent LIT. All patients had undergone investigation of the etiology of the pregnancy losses according to a specific protocol. These etiologic factors were compared between those whose pregnancy outcome was successful and those who had a further miscarriage. The comparison between the groups was performed by Kruskal-Wallis, Fisher exact and Chi-square tests. Perinatal outcome data were collected for the successful pregnancies. One-hundred six patients were included. The mean number (±SD) of previous pregnancies, deliveries and miscarriages in all patients were 2.73 ± 0.8, 0.19 ± 0.4 and 2.54 ± 0.6, respectively. A successful pregnancy outcome after lymphocyte therapy occurred in 82 patients (group I), while 24 (22.6%) sustained a further miscarriage (group II). There was no statistical difference in the genetic, anatomic and hormonal causes of miscarriage between the groups (p > 0.05). Antinuclear (ANA) and antithyroglobulin (TgAb) autoantibodies occurred more frequently in group II (p = 0.0010 and p = 0.0024, respectively). Of those with successful pregnancies, 11 women (13.4%) had a preterm delivery. The mean birth weight was 3036.4 ± 498.6 g. In patients with recurrent miscarriage treated with LIT, the presence of ANA and TgAb was a risk factor for further pregnancy loss. Perinatal outcomes in those whose pregnancies continued were favorable.

(PDF emailed within 0-6 h: $19.90)

Accession: 055579525

Download citation: RISBibTeXText

PMID: 25005857

DOI: 10.3109/14767058.2014.943175


Related references

Perinatal outcomes in a subsequent pregnancy among women who have experienced recurrent miscarriage: a retrospective cohort study. Human Reproduction 30(5): 1239-1245, 2016

The number of previous miscarriage doest affects the autoantibodies profile and gestational outcomes in couples treated for recurrent miscarriages with paternal lymphocyte immunization. Journal of Reproductive Immunology 94(1): 88-0, 2012

The risk factors of miscarriage and obstetrical outcomes of intrauterine normal pregnancy following heterotopic pregnancy management. Medicine 97(37): E12233, 2018

Antiphosphatidylethanolamine antibodies might not be an independent risk factor for further miscarriage in patients suffering recurrent pregnancy loss. Journal of Reproductive Immunology 85(2): 186-192, 2010

Further insights into the role of the annexin A5 M2 haplotype as recurrent pregnancy loss factor, assessing timing of miscarriage and partner risk. Fertility and Sterility 100(5): 1321-1325, 2013

Recurrent pregnancy loss evaluation combined with 24-chromosome microarray of miscarriage tissue provides a probable or definite cause of pregnancy loss in over 90% of patients. Human Reproduction 33(4): 579-587, 2018

Previous miscarriage and stillbirth as risk factors for other unfavourable outcomes in the next pregnancy. British Journal of Obstetrics & Gynaecology 99(10): 808-812, 1992

Lymphocyte immunotherapy in the treatment of recurrent miscarriage: systematic review and meta-analysis. Archives of Gynecology and Obstetrics 295(2): 511-518, 2016

The immunological aspects alterations after lymphocyte immunotherapy of the women who suffering recurrent miscarriage. Journal of Reproductive Immunology 90(2): 150-151, 2011

Does Miscarriage in an Initial Pregnancy Lead to Adverse Obstetric and Perinatal Outcomes in the Next Continuing Pregnancy?. Obstetric Anesthesia Digest 29(4): 194-195, 2009

Does miscarriage in an initial pregnancy lead to adverse obstetric and perinatal outcomes in the next continuing pregnancy?. Bjog 115(13): 1623-1629, 2008

The expression of Th1- and Th2-related chemokine receptors in women with recurrent miscarriage: the impact of lymphocyte immunotherapy. American Journal of Reproductive Immunology 64(2): 104-112, 2010

Comprehensive analysis of peripheral blood lymphocytes in 76 women with recurrent miscarriage before and after lymphocyte immunotherapy. American Journal of Reproductive Immunology 68(2): 164-174, 2012

Pregnancy outcomes of couples treated for recurrent miscarriages with paternal lymphocyte immunization. Journal of Reproductive Immunology 94(1): 87-0, 2012

Perinatal outcomes of women with a prior history of unexplained recurrent miscarriage. Journal of Maternal-Fetal and Neonatal Medicine 28(5): 522-525, 2016